FindTrial
Sign In

Effect of solifenacin for prevention of catheter related bladder discomfort after transurethral resection of bladder tumor in bladder cancer patients: multicenter, randomized, prospective, 2 group clinical trial

Effect of solifenacin for prevention of catheter related bladder discomfort after transurethral resection of bladder tumor in bladder cancer patients: multicenter, randomized, prospective, 2 group clinical trial

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
CRIS
Registry ID
KCT0000498
Enrollment
172
Registered
2012-08-03
Start date
2012-04-04
Completion date
Unknown
Last updated
2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : Patients undergoing TURBT under general or spinal anaesthesia were randomly assigned to two groups: Group S and Group C. Group S received solifenacin 5mg orally before surgery and 24hrs and 48h

Sponsors

National Cancer Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients undergoing transurethral resection of the bladder tumor under general or spinal anaesthesia

Exclusion criteria

Exclusion criteria: 1) past analgesics use history, 2) anticholinergics user due to OAB, 3) brain and spinal disease, 4) renal dysfunction, 5) hepatic dysfunction, 6) can not access the pain, 7) postvoiding volume >200cc 8) Qmax T2 10) no complete resection case

Design outcomes

Primary

MeasureTime frame
Bladder discomfort—

Secondary

MeasureTime frame
Pain was assessed using a VAS. ;Standardized postoperative analgesia ;Side effect or complication—

Countries

Korea, Republic of

Contacts

Public ContactJae Min Chung

Kosin University Gospel Hospital

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026